Product Overview
Clone: GR233/Rabbit/Monoclonal
GeneBio’s recombinant antibody binds Somatostatin Receptor 2 (SSTR2), a protein expressed in the secretory cells of the pancreas and the neurons of the central nervous system. Somatostatin (SSTR2) is overexpressed in neuroendocrine tumors and can help predict response to targeted radiopeptide therapy. Somatostatin (SSTR2) expression can also play a role in guiding imaging studies and treatment choice.
Somatostatin receptor 2 (SSTR2) expression has been well demonstrated in most gastroenteropancreatic neuroendocrine tumors, with the exception of rectal neuroendocrine tumors. In studies, approximately two-thirds of rectal neuroendocrine tumors expressed SSTR2. SSTR2 expression was significantly associated with favorable behavior and good overall survival in patients with rectal neuroendocrine tumors. Furthermore, SSTR2 expression can be used as prognostic factors. When metastatic disease occurs, SSTR2 expression can be used a possible target for somatostatin analogues.
SSTRs (somatostatin receptors) represent a family of G protein-coupled receptors which mediate the diverse biological actions of somatostatin (SST). There are five distinct subtypes of SSTRs that bind two natural ligands, SST-14 and SST-28. SSTR2 gives rise to spliced variants, SSTR2A and 2B. Somatostatin (SSTRs) share common signaling pathways such as the ability to inhibit adenylyl cyclase via GTP binding proteins. Individual target cells typically express more than one SSTR subtype and often all five isoforms. Subtypes of Somatostatin (SSTR) can form functional homo- and heterodimers.
